Hydrochloric Acid

Hydrochloric Acid

SCHEMBL565665

Cl.[Rh].c1ccc(P(c2ccccc2)c2ccccc2)cc1.c1ccc(P(c2ccccc2)c2ccccc2)cc1.c1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 known ✓ P03372 4/20 0.60
ESR2 known ✓ Q92731 4/20 0.60
GAA known ✓ P10253 1/20 0.46
DRD1 known ✓ P21728 2/20 0.34
CA2 known ✓ P00918 2/20 0.32
GLA known ✓ P06280 1/20 0.32
ACHE known ✓ P22303 1/20 0.32
TDP1 Q9NUW8 3/20 0.86
CYP3A4 P08684 1/20 0.86
KDM4E B2RXH2 1/20 0.46
NPSR1 Q6W5P4 1/20 0.35
ALDH1A1 P00352 4/20 0.35
TSHR P16473 4/20 0.32
CA1 P00915 2/20 0.32
CA9 Q16790 2/20 0.32
LMNA P02545 2/20 0.32
CA12 O43570 1/20 0.32
CA3 P07451 1/20 0.32
CA4 P22748 1/20 0.32
CA14 Q9ULX7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7202751 1.00 TDP1 (0.86) TDP1CYP3A4ESR1ESR2KDM4E
Hydrochloric Acid SCHEMBL8762761 1.00 TDP1 (0.86) TDP1CYP3A4ESR1ESR2KDM4E
Hydrochloric Acid SCHEMBL1524610 1.00 TDP1 (0.86) TDP1CYP3A4ESR1ESR2KDM4E
Hydrochloric Acid SCHEMBL7930992 0.96 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
SCHEMBL852493 0.96 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
Hydrochloric Acid SCHEMBL8372285 0.96 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
SCHEMBL1013946 0.96 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
Hydrochloric Acid SCHEMBL9414432 0.96 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
Hydrochloric Acid SCHEMBL1584554 0.96 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
SCHEMBL1982595 0.96 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 529 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11426712-B2 Fischer-Tropsch synthesis catalyst containing nitride support, preparation method therefor and use thereof SYNFUELS CHINA TECHNOLOGY CO., LTD. (CN) 2022-08-30 US claimed
US-20120035385-A1 SELECTING CATALYST AND CONDITIONS RINARD CHAUNCEY J (US) 2012-02-09 US claimed
US-20110021460-A1 SELECTIVE HYDROSILYLATION METHOD AND PRODUCT MOMENTIVE PERFORMANCE MATERIALS, INC. 2011-01-27 US claimed
US-7605219-B2 Selective hydrosilylation method with alcohol or epoxide reactant and product MOMENTIVE PERFORMANCE MATERIALS (US) 2009-10-20 US claimed
US-7479559-B2 3-[-2-(Piperazin-1-yl)benzyl]pyrrolidin-2-one derivatives; antidepressants, anxiolytic agents; obsessive compulsive disorder, psychological disorders, phobias; 5-HT1 agonist or antagonists; side effect reduction, in particular cardiac QTc prolongation; hydrogenation PFIZER INC. (US) 2009-01-20 US claimed
US-20080081924-A1 SELECTIVE MOLAR EXCESS HYDROSILYLATION METHOD AND PRODUCT MOMENTIVE PERFORMANCE MATERIALS INC. 2008-04-03 US claimed
US-20080076939-A1 Two-step process of reacting a dihydroorganosiloxane with a terminally unsaturated compound in the presence of a rhodium catalyst and then with a different unsaturated compound to form an assymetrically disubstitued siloxane; one of the unsaturated compounds is an alkenyl polyalkylene oxide MOMENTIVE PERFORMANCE MATERIALS INC. 2008-03-27 US claimed
US-20080076896-A1 SELECTIVE HYDROSILYLATION METHOD AND PRODUCT MOMENTIVE PERFORMANCE MATERIALS INC. 2008-03-27 US claimed
US-20080076894-A1 SELECTIVE HYDROSILYLATION METHOD WITH ALCOHOL OR EPOXIDE REACTANT AND PRODUCT MOMENTIVE PERFORMANCE MATERIALS INC. 2008-03-27 US claimed
US-20080033136-A1 SELECTIVE HYDROSILYLATION CONDITIONS MOMENTIVE PERFORMANCE MATERIALS INC. 2008-02-07 US claimed
WO-2006120472-A2 NOVEL BETA-STEROID COMPOUNDS GUY'S AND ST THOMAS'NHS FOUNDATION TRUST (GB) 2006-11-16 WO claimed
US-20050245521-A1 Novel benayl(idene)-lactam derivatives PFIZER INC. 2005-11-03 US claimed
US-6838182-B2 Low temperature, fast curing silicone compositions HENKEL CORPORATION (US) 2005-01-04 US claimed
US-6573328-B2 Miniature electronics, blend of silicon, crosslinker, catalyst LOCTITE CORPORATION 2003-06-03 US claimed
US-5312885-A Complex rhodium catalyst SHIN-ETSU CHEMICAL CO., LTD. (JP) 1994-05-17 US claimed
US-4879070-A HYDROGEN, CARBON DIOXIDE, TERTIARY AMINE, RHODIUM-ORGANOPHOSPHORUS CATALYST BP CHEMICALS LIMITED (GB) 1989-11-07 US claimed
EP-0219949-A2 Preparation of high-purity silyl ketene acetals DOW CORNING CORPORATION (US) 1987-04-29 EP claimed
US-4579963-A Organosilicon compound and a room temperature curable organopolysiloxane composition formulated therewith SHIN-ETSU CHEMICAL CO., LTD. (JP) 1986-04-01 US claimed
US-4544770-A OF UNSATURATED PHOSPHONIUM COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 1985-10-01 US claimed
US-4031150-A Catalytic dimerization of norbornadiene to Binor-S SUNTECH, INC. (US) 1977-06-21 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035385-A1 SELECTING CATALYST AND CONDITIONS ALG3, MMS19, CAD ESR1 477/4885ESR2 2354/4885GAA 2680/4885
US-20080076939-A1 Two-step process of reacting a dihydroorganosiloxane with a terminally unsaturated compound in the presence of a rhodium catalyst and then with a different unsaturated compound to form an assymetrically disubstitued siloxane; one of the unsaturated compounds is an alkenyl polyalkylene oxide SQLE, HRH3, HMOX2 ESR1 677/4885ESR2 376/4885GAA 4147/4885
US-20050245521-A1 Novel benayl(idene)-lactam derivatives HTR1E, HTR1D, HTR1A ESR1 351/4885ESR2 329/4885GAA 3035/4885
US-20110021460-A1 SELECTIVE HYDROSILYLATION METHOD AND PRODUCT HRH3, HRH4, H1-0 ESR1 1082/4885ESR2 971/4885GAA 4250/4885
US-20080081924-A1 SELECTIVE MOLAR EXCESS HYDROSILYLATION METHOD AND PRODUCT HRH3, HRH4, B2M ESR1 1274/4885ESR2 1064/4885GAA 4479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.